IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
Phase 2
55
about 9.6 years
18–40
Female only
2 sites in NY, UT
What this study is about
Researchers are testing if adding certolizumab, an anti-tumor necrosis factor-alpha drug, to usual treatment (heparin and aspirin) improves pregnancy outcomes for women with antiphospholipid syndrome (APS) who have repeatedly positive tests for lupus anticoagulant (LAC). The goal is to enroll 55 women. The trial will last approximately 3515 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Certolizumab Pegol
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
certolizumab pegol
injection (Injection)
Reproductive Health, Immune